Abstract 1271P
Background
Understanding the associates and causes of progression after first-line treatment in EGFR-mutant advanced NSCLC remains a critical yet elusive endeavor. In this study, we employed a comprehensive approach integrating machine learning classification and causal inference analysis to unveil the determinants of progression in this patient cohort.
Methods
Retrospective data from eleven academic centers were gathered to compile a cohort of EGFR mutant patients. Classical patient features, treatment characteristics, and the neutrophil to lymphocyte ratio (NLR) at the onset of first-line treatment were analyzed. Fifteen machine learning algorithms were employed to identify the optimal model, evaluated based on F1 score and area under the curve (AUC). Additionally, Linear Non-Gaussian Acyclic Model (LINGAM) was utilized for causal inference analysis to delineate the causal relationships driving progression.
Results
Among 333 patients initially evaluated, 205 cases were deemed suitable for machine learning analysis after accounting for missing data and follow-up duration. Linear discriminant analysis emerged as the most accurate model, achieving an AUC of 0.74 and an F1 score of 0.77. The top three influential variables identified by this model were smoking status, NLR category, and type of first-line treatment with variable importance scores of 1.2, 0.8, and 0.6, respectively. Moreover, LINGAM analysis revealed NLR category, smoking status, and gender as causal factors for progression, with causal estimate scores of -0.20, -0.17, and -0.04, respectively.
Conclusions
This study represents a pioneering effort in utilizing machine learning to explore the determinants of progression after first-line treatment in EGFR-mutant, advanced NSCLC. Our findings underscore the roles of smoking status, NLR category, and type of first-line treatment in driving progression. Furthermore, the causal inference analysis sheds light on smoking status, NLR category, and gender as causally significant factors. This understanding paves the way for elucidating the pathogenesis and developing novel therapeutic strategies for EGFR-mutant advanced NSCLC.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work the authors used ChatGpt 3.5 in order to enhance readibility. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1302P - MET×MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
Presenter: Byoung Chul Cho
Session: Poster session 05
1303P - METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence
Presenter: Xiuning Le
Session: Poster session 05
1304P - Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience
Presenter: Abdulrahman Alghabban
Session: Poster session 05
1305P - Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
Presenter: Ferdinandos Skoulidis
Session: Poster session 05
1306P - Trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer: A single-center, open-label, single-cohort study
Presenter: Baohui Han
Session: Poster session 05
Resources:
Abstract
1308P - Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations
Presenter: Lea Ruge
Session: Poster session 05
1309P - A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A
Presenter: Jonathan Riess
Session: Poster session 05
1310P - SHR-A1921: A trophoblast cell-surface antigen 2 (TROP-2) targeted antibody-drug conjugate (ADC) for the treatment of advanced NSCLC
Presenter: Jie Wang
Session: Poster session 05
1311P - Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab ± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial
Presenter: Delvys Rodriguez Abreu
Session: Poster session 05